Stockscreener 앱 받기
4.67
3.11%
-0.15
시간 외 거래:
4.68
0.010
+0.21%
전일 마감가:
$4.82
열려 있는:
$4.82
하루 거래량:
390.29K
Relative Volume:
1.43
시가총액:
$200.27M
수익:
-
순이익/손실:
$-19.90M
주가수익비율:
-8.8113
EPS:
-0.53
순현금흐름:
$-19.80M
1주 성능:
+13.35%
1개월 성능:
+27.95%
6개월 성능:
-25.40%
1년 성능:
+39.40%
1일 변동 폭
$4.41
$4.935
1주일 범위
$4.15
$5.09
52주 변동 폭
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
명칭
Diamedica Therapeutics Inc
전화
(763) 496-5454
주소
301 CARLSON PARKWAY, MINNEAPOLIS, MN
DMAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
4.67 | 243.03M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-06-22 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 개시 | Oppenheimer | Outperform |
| 2021-02-17 | 개시 | ROTH Capital | Buy |
| 2020-10-30 | 개시 | Guggenheim | Buy |
| 2020-07-08 | 개시 | Maxim Group | Buy |
| 2019-04-30 | 개시 | Dougherty & Company | Buy |
| 2019-03-05 | 개시 | Lake Street | Buy |
모두보기
Diamedica Therapeutics Inc 주식(DMAC)의 최신 뉴스
What to expect from DiaMedica Therapeutics Inc. in the next 30 daysFree Chart Breakout Buy Signal Detection - Newser
Technical analysis overview for DiaMedica Therapeutics Inc. stockTrade Alert System with Volume Analysis - Newser
What data driven models say about DiaMedica Therapeutics Inc.’s futureTrend Analysis for Safer Market Entries - Newser
Screener Results Flag DiaMedica Therapeutics Inc. as OversoldDaily Chart Pattern Stock Forecast Shows Bullish Setup - metal.it
Full technical analysis of DiaMedica Therapeutics Inc. stockAI Short-Term Gain Forecast with Data - Newser
Is this a good reentry point in DiaMedica Therapeutics Inc.Buy Opportunity Forecast for Fast Traders - Newser
Can momentum traders help lift DiaMedica Therapeutics Inc.Free Low Risk Buy Zone Opportunity Watch - Newser
Published on: 2025-08-09 04:59:23 - Newser
DiaMedica Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
What indicators show strength in DiaMedica Therapeutics Inc.Conservative Equity Setup with Signal Analysis - Newser
Momentum divergence signals in DiaMedica Therapeutics Inc. chartCapital Growth Summary Over Five Years - Newser
What’s the recovery path for long term holders of DiaMedica Therapeutics Inc.Consistent Gain Plan with AI Support - Newser
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
What makes DiaMedica Therapeutics Inc. stock price move sharplyLong Term Stock Growth Plan Suggestions - Newser
Intraday pattern recognizer results for DiaMedica Therapeutics Inc.Swing Entry Insight With Forecast Accuracy - Newser
Diamedica Therapeutics shares rise 3.12% intraday after appointing Julie Krop, MD, as Chief Medical Officer. - AInvest
DiaMedica Appoints New Chief Medical Officer - TipRanks
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer. - AInvest
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Business Wire
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - Lelezard
Diamedica Therapeutics To Report Second Quarter 2025 Financial Results And Provide A Business Update August 13, 2025 - TradingView
Press Release: DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - 富途牛牛
Can trapped investors hope for a rebound in DiaMedica Therapeutics Inc.Price Action Trading with Volume Confirmation - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityLow Risk Stock Selection Strategy Guide - Newser
DiaMedica Therapeutics Inc. Stock Analysis and ForecastMaximize returns with strategic stock selection - Jammu Links News
What drives DiaMedica Therapeutics Inc. stock priceCapitalize on trading strategies that deliver - Jammu Links News
What analysts say about DiaMedica Therapeutics Inc. stockDiscover hidden gems in the stock market - Jammu Links News
How strong is DiaMedica Therapeutics Inc. company’s balance sheetExplosive market performance - Jammu Links News
How does DiaMedica Therapeutics Inc. compare to its industry peersStay informed with expert market forecasts - Jammu Links News
What are the latest earnings results for DiaMedica Therapeutics Inc.Double-digit growth - Jammu Links News
What are DiaMedica Therapeutics Inc. company’s key revenue driversAchieve breakthrough profits with smart strategies - Jammu Links News
Is DiaMedica Therapeutics Inc. stock overvalued or undervaluedFree Stock Chart Pattern Guide - Jammu Links News
How volatile is DiaMedica Therapeutics Inc. stock compared to the marketCapitalize on market trends early - Jammu Links News
What is the risk reward ratio of investing in DiaMedica Therapeutics Inc. stockSuperior stock selection - Jammu Links News
DiaMedica Therapeutics to Sell 8.61 Million Common Shares for Shareholders. - AInvest
What are the technical indicators suggesting about DiaMedica Therapeutics Inc.Market-leading profit generation - Jammu Links News
What are analysts’ price targets for DiaMedica Therapeutics Inc. in the next 12 monthsGet exclusive access to expert stock recommendations - Jammu Links News
Diamedica Therapeutics Inc (DMAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):